10.64
-0.69 (-6.05%)
| Previous Close | 11.32 |
| Open | 10.97 |
| Volume | 4,980,992 |
| Avg. Volume (3M) | 8,021,838 |
| Market Cap | 3,446,243,840 |
| Price / Sales | 51.68 |
| Price / Book | 4.10 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Operating Margin (TTM) | -1,479.57% |
| Diluted EPS (TTM) | -0.560 |
| Quarterly Revenue Growth (YOY) | -57.50% |
| Total Debt/Equity (MRQ) | 6.63% |
| Current Ratio (MRQ) | 10.15 |
| Operating Cash Flow (TTM) | -78.40 M |
| Levered Free Cash Flow (TTM) | -189.06 M |
| Return on Assets (TTM) | -12.94% |
| Return on Equity (TTM) | -15.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | AbCellera Biologics Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.97% |
| % Held by Institutions | 44.79% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOOTH ANDREW | 11.38 | - | 37,200 | 423,336 |
| HAYDEN MICHAEL R | 10.36 | 9.76 | -3,613 | -7,663 |
| MONTALBANO JOHN S. | 11.12 | - | 10,000 | 111,200 |
| Aggregate Net Quantity | 43,587 | |||
| Aggregate Net Value ($) | 526,873 | |||
| Aggregate Avg. Buy ($) | 10.95 | |||
| Aggregate Avg. Sell ($) | 9.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MONTALBANO JOHN S. | Director | 18 Aug 2026 | Buy (+) | 10,000 | 11.12 | 111,200 |
| BOOTH ANDREW | Officer | 14 Aug 2026 | Buy (+) | 37,200 | 11.38 | 423,336 |
| HAYDEN MICHAEL R | Director | 12 Aug 2026 | Buy (+) | 46,387 | 10.36 | 480,337 |
| HAYDEN MICHAEL R | Director | 11 Aug 2026 | Disposed (-) | 50,000 | 9.76 | 488,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |